Skip to main content

Articles

Page 10 of 67

  1. Patient-Reported Outcomes (PROs) have been developed to numerically quantify disability, impact and quality of life. They have been widely used in migraine clinical trials. However, we still do not know which ...

    Authors: Alicia Alpuente, Victor J Gallardo, Edoardo Caronna, Marta Torres-Ferrus and Patricia Pozo-Rosich
    Citation: The Journal of Headache and Pain 2021 22:151
  2. An imbalance between inhibitory and excitatory neurometabolites has been implicated in chronic pain. Prior work identified elevated levels of Gamma-aminobutyric acid + macromolecules (“GABA+”) using magnetic r...

    Authors: Aimie L. Peek, Andrew M. Leaver, Sheryl Foster, Nicolaas A. Puts, Georg Oeltzschner, Luke Henderson, Graham Galloway, Karl Ng, Kathryn Refshauge and Trudy Rebbeck
    Citation: The Journal of Headache and Pain 2021 22:150
  3. Calcitonin gene-related peptide ligand/receptor (CGRP) antibodies effectively reduce headache frequency in migraine. It is understood that they act peripherally, which raises the question whether treatment mer...

    Authors: Anne Thiele, Lara Klehr, Sebastian Strauß, Anselm Angermaier, Ulf Schminke, Martin Kronenbuerger, Steffen Naegel and Robert Fleischmann
    Citation: The Journal of Headache and Pain 2021 22:149
  4. Patients with visual snow syndrome (VSS) suffer from a debilitating continuous (“TV noise-like”) visual disturbance. They report problems with vision at night and palinopsia despite normal visual acuity. The u...

    Authors: Ozan E. Eren, Andreas Straube, Florian Schöberl, Ruth Ruscheweyh, Thomas Eggert and Christoph J. Schankin
    Citation: The Journal of Headache and Pain 2021 22:148
  5. Accumulating studies have indicated a wide range of brain alterations with respect to the structure and function of classic trigeminal neuralgia (CTN). Given the dynamic nature of pain experience, the explorat...

    Authors: Pengfei Zhang, Yanli Jiang, Guangyao Liu, Jiao Han, Jun Wang, Laiyang Ma, Wanjun Hu and Jing Zhang
    Citation: The Journal of Headache and Pain 2021 22:147
  6. Purinergic P2X7 receptor plays an important role in migraine pathophysiology. Yet precise molecular mechanism underlying P2X7R signaling in migraine remains unclear. This study explores the hypothesis that P2X...

    Authors: Lingdi Nie, Dongqing Ma, John P. Quinn and Minyan Wang
    Citation: The Journal of Headache and Pain 2021 22:146
  7. Migraine represents one of the most prevalent neurological conditions worldwide. It is a disabling condition with high impact on the working situation of migraineurs. Interestingly, gender-related differences ...

    Authors: Oreste Affatato, Maud Miguet, Helgi B. Schiöth and Jessica Mwinyi
    Citation: The Journal of Headache and Pain 2021 22:145
  8. Transcranial direct current stimulation (tDCS) could counteract the pathophysiological triggers of migraine attacks by modulating cortical excitability. Several pilot randomized controlled trials (RCTs) assess...

    Authors: Raffaele Ornello, Valeria Caponnetto, Susanna Ratti, Giulia D’Aurizio, Chiara Rosignoli, Francesca Pistoia, Michele Ferrara, Simona Sacco and Aurora D’Atri
    Citation: The Journal of Headache and Pain 2021 22:144
  9. Patients with migraine have an increased relative risk of cardio- and cerebrovascular events, and some migraine treatments may exacerbate this risk. The primary objective of this analysis was to determine whet...

    Authors: Timothy R. Smith, Egilius L. H. Spierings, Roger Cady, Joe Hirman, Anders Ettrup and Vivienne Shen
    Citation: The Journal of Headache and Pain 2021 22:143
  10. Migraine is a common brain disorder but reliable diagnostic biomarkers in blood are still lacking. Our aim was to identify, using proton nuclear magnetic resonance (1H-NMR) spectroscopy, metabolites in serum that...

    Authors: Aster V. E. Harder, Lisanne S. Vijfhuizen, Peter Henneman, Ko Willems van Dijk, Cornelia M. van Duijn, Gisela M. Terwindt and Arn M. J. M. van den Maagdenberg
    Citation: The Journal of Headache and Pain 2021 22:142
  11. Although migraine is less common in older people, preventive treatment of migraine in these individuals may be more challenging due to the presence of multiple comorbidities and polypharmacy. Additionally, evi...

    Authors: Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow and Christian Lampl
    Citation: The Journal of Headache and Pain 2021 22:141

    The Correction to this article has been published in The Journal of Headache and Pain 2022 23:57

  12. Health care costs of migraine constitute a major issue in health economics. Several publications analyzed health care costs for adult migraine patients, based on questionnaires or secondary (health insurance) ...

    Authors: Viola Obermeier, Monika Murawski, Florian Heinen, Mirjam N. Landgraf, Andreas Straube, Rüdiger von Kries and Ruth Ruscheweyh
    Citation: The Journal of Headache and Pain 2021 22:140
  13. Occipital transcranial direct current stimulation (tDCS) is an effective and safe treatment for migraine attack prevention. Structural brain alterations have been found in migraineurs in regions related to pai...

    Authors: Simon Schading, Heiko Pohl, Andreas Gantenbein, Roger Luechinger, Peter Sandor, Franz Riederer, Patrick Freund and Lars Michels
    Citation: The Journal of Headache and Pain 2021 22:139
  14. Pain is generally concomitant with an inflammatory reaction at the site where the nociceptive fibers are activated. Rodent studies suggest that a sterile meningeal inflammatory signaling cascade may play a rol...

    Authors: Şefik Evren Erdener, Zeynep Kaya and Turgay Dalkara
    Citation: The Journal of Headache and Pain 2021 22:138
  15. Post-traumatic headache (PTH) is a very common symptom following mild traumatic brain injury (mTBI), yet much remains unknown about the underlying pathophysiological mechanisms of PTH. Neuroimaging studies sug...

    Authors: Fengfang Li, Liyan Lu, Song’an Shang, Huiyou Chen, Peng Wang, Vijaya Prakash Muthaiah, Xindao Yin and Yu-Chen Chen
    Citation: The Journal of Headache and Pain 2021 22:137
  16. General practitioners (GPs) diagnose and manage a majority of headache patients seeking health care. With the aim to understand the potential for clinical improvement and educational needs, we performed a stud...

    Authors: Espen Saxhaug Kristoffersen, Kashif Waqar Faiz, Jakob Møller Hansen, Erling Andreas Tronvik, Jan C. Frich, Christofer Lundqvist and Bendik Slagsvold Winsvold
    Citation: The Journal of Headache and Pain 2021 22:136
  17. Headache affects 90–99% of the population. Based on the question “Do you think that you never ever in your whole life have had a headache?” 4% of the population say that they have never experienced a headache....

    Authors: Isa Amalie Olofsson, Jeppe Hvedstrup, Katrine Falkenberg, Mona Ameri Chalmer, Henrik Winther Schytz, Miguel Benjamin Pedersen, Henrik Ullum, Ole Birger Pedersen, Jes Olesen and Thomas Folkmann Hansen
    Citation: The Journal of Headache and Pain 2021 22:134
  18. Erenumab, the first-in-class fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the prophylactic treatment of migraine in adults in...

    Authors: Andreas Straube, Philipp Stude, Charly Gaul, Katrin Schuh and Mirja Koch
    Citation: The Journal of Headache and Pain 2021 22:133
  19. Lasmiditan (LTN) is a selective 5-HT1F receptor agonist for the acute treatment of migraine in adults. We present detailed safety findings from the placebo-controlled, double-blind Phase 3 study, of LTN treatment...

    Authors: C Tassorelli, S Bragg, JH Krege, EG Doty, PA Ardayfio, D Ruff, SA Dowsett and T Schwedt
    Citation: The Journal of Headache and Pain 2021 22:132
  20. Authors: Sara Bottiroli, Roberto De Icco, Gloria Vaghi, Stefania Pazzi, Elena Guaschino, Marta Allena, Natascia Ghiotto, Daniele Martinelli, Cristina Tassorelli and Grazia Sances
    Citation: The Journal of Headache and Pain 2021 22:131

    The original article was published in The Journal of Headache and Pain 2021 22:114

  21. In this study, we aimed to investigate the spontaneous neural activity in the conventional frequency band (0.01−0.08 Hz) and two sub-frequency bands (slow-4: 0.027–0.073 Hz, and slow-5: 0.01–0.027 Hz) in tensi...

    Authors: Shuxian Zhang, Huayun Li, Qinyan Xu, Chao Wang, Xue Li, Jiawei Sun, Yaqi Wang, Tong Sun, Qianqian Wang, Chengcheng Zhang, Jili Wang, Xize Jia and Xihe Sun
    Citation: The Journal of Headache and Pain 2021 22:129
  22. Several drugs are available for the preventive treatment of both episodic and chronic migraine. The choice of which therapy to initiate first, second, or third is not straightforward and is based on multiple f...

    Authors: Fenne Vandervorst, Laura Van Deun, Annelies Van Dycke, Koen Paemeleire, Uwe Reuter, Jean Schoenen and Jan Versijpt
    Citation: The Journal of Headache and Pain 2021 22:128
  23. Migraine sufferers face difficulties getting appropriate care and treatment. Migraine is associated with reduced gray matter volume (GMV) in several brain regions, which could be related to various clinical ch...

    Authors: Shana A.B. Burrowes, Olga Goloubeva, Michael L Keaser, Jennifer A. Haythornthwaite and David A. Seminowicz
    Citation: The Journal of Headache and Pain 2021 22:127
  24. The MIDAS is the most used questionnaire to evaluate migraine-related disability, but its utility to assess treatment response remains unclear. Our aim was to estimate the MIDAS’ minimal important change (MIC)...

    Authors: Gabriela F. Carvalho, Kerstin Luedtke and Tobias Braun
    Citation: The Journal of Headache and Pain 2021 22:126
  25. To compare symptoms of clinical androgen deficiency between men with migraine, men with cluster headache and non-headache male controls.

    Authors: Iris E. Verhagen, Roemer B. Brandt, Carlijn M. A. Kruitbosch, Antoinette MaassenVanDenBrink, Rolf Fronczek and Gisela M. Terwindt
    Citation: The Journal of Headache and Pain 2021 22:125

    The Correction to this article has been published in The Journal of Headache and Pain 2021 22:135

  26. Migraine has been associated with cardiovascular disease (CVD) events among middle-aged adults. The objective of this study was to determine the risk for ischemic stroke and coronary heart disease (CHD) events...

    Authors: Emily C. McKinley, Christine L. Lay, Robert S. Rosenson, Ligong Chen, Victoria Chia, Lisandro D. Colantonio, Paul Muntner, Robert Urman and Michael E. Farkouh
    Citation: The Journal of Headache and Pain 2021 22:124
  27. Obesity confers adverse effects to every system in the body including the central nervous system. Obesity is associated with both migraine and idiopathic intracranial hypertension (IIH). The mechanisms underly...

    Authors: Connar Stanley James Westgate, Ida Marchen Egerod Israelsen, Rigmor Højland Jensen and Sajedeh Eftekhari
    Citation: The Journal of Headache and Pain 2021 22:123
  28. Brain arteriovenous malformations (AVMs) consist of abnormal connections between arteries and veins via an interposing nidus. While hemorrhage is the most common presentation, unruptured AVMs can present with ...

    Authors: Benjamin N Africk, Daniel M Heiferman, Amy W Wozniak, Faraz Behzadi, Matthew S Ballard, Joshua M Chazaro, Brandon M Zsigray, Rachyl M Shanker, Matthew R Reynolds, Douglas E Anderson and Joseph C Serrone
    Citation: The Journal of Headache and Pain 2021 22:122
  29. Calcitonin gene-related peptide (CGRP) is expressed throughout the body and is a known mediator of migraine, exerting this biological effect through activation of trigeminovascular, meningeal and associated ne...

    Authors: Jason C. Ray, Penelope Allen, Ann Bacsi, Julian J. Bosco, Luke Chen, Michael Eller, Hock Kua, Lyndell L. Lim, Manjit S. Matharu, Mastura Monif, Martin Ruttledge, Richard J. Stark and Elspeth J. Hutton
    Citation: The Journal of Headache and Pain 2021 22:121
  30. In daily practice, anti-CGRP monoclonal antibodies (MAbs) may be useful in chronic migraine (CM) with medication overuse (MO), but data is limited. We evaluated their effectiveness in a real-life clinical cohort.

    Authors: Edoardo Caronna, Victor José Gallardo, Alicia Alpuente, Marta Torres-Ferrus and Patricia Pozo-Rosich
    Citation: The Journal of Headache and Pain 2021 22:120
  31. Migraine is a common neurological disease with extremely debilitating, but fully reversible symptoms. Women suffer from migraine more often than men. It was assumed that fluctuation of oestrogen level during m...

    Authors: Magdalena Kobus, Aneta Sitek, Bogusław Antoszewski, Jacek Rożniecki, Jacek Pełka and Elżbieta Żądzińska
    Citation: The Journal of Headache and Pain 2021 22:119
  32. Headache is the predominant disabler in idiopathic intracranial hypertension (IIH). The aim was to characterise headache and investigate the association with intracranial pressure.

    Authors: S. P. Mollan, B. R. Wakerley, Z. Alimajstorovic, J. Mitchell, R. Ottridge, A. Yiangou, M. Thaller, A. Gupta, O. Grech, G. Lavery, K. Brock and A. J. Sinclair
    Citation: The Journal of Headache and Pain 2021 22:118
  33. Recent data suggest that gene expression profiles of peripheral white blood cells can reflect changes in the brain. We aimed to analyze the transcriptome of peripheral blood mononuclear cells (PBMC) and change...

    Authors: Timea Aczél, Tamás Körtési, József Kun, Péter Urbán, Witold Bauer, Róbert Herczeg, Róbert Farkas, Krisztián Kovács, Barna Vásárhelyi, Gellért B. Karvaly, Attila Gyenesei, Bernadett Tuka, János Tajti, László Vécsei, Kata Bölcskei and Zsuzsanna Helyes
    Citation: The Journal of Headache and Pain 2021 22:117
  34. Authors: Lotte Skytte Krøll, Henriette Edemann Callesen, Louise Ninett Carlsen, Kirsten Birkefoss, Dagmar Beier, Henrik Wulff Christensen, Mette Jensen, Hanna Tómasdóttir, Hanne Würtzen, Christel Vesth Høst and Jakob Møller Hansen
    Citation: The Journal of Headache and Pain 2021 22:116

    The original article was published in The Journal of Headache and Pain 2021 22:96

  35. Authors: Anne-Sophie Wattiez, Olivia J. Gaul, Adisa Kuburas, Erik Zorrilla, Jayme S. Waite, Bianca N. Mason, William C. Castonguay, Mengya Wang, Bennett R. Robertson and Andrew F. Russo
    Citation: The Journal of Headache and Pain 2021 22:115

    The original article was published in The Journal of Headache and Pain 2021 22:62

  36. Monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide (CGRP) pathway represent the first disease-specific preventive migraine therapy. Growing evidence suggests that they are effective in ...

    Authors: Sara Bottiroli, Roberto De Icco, Gloria Vaghi, Stefania Pazzi, Elena Guaschino, Marta Allena, Natascia Ghiotto, Daniele Martinelli, Cristina Tassorelli and Grazia Sances
    Citation: The Journal of Headache and Pain 2021 22:114

    The Correction to this article has been published in The Journal of Headache and Pain 2021 22:131

  37. Chronic migraine (CM) and episodic migraine (EM) are associated with substantial headache-related disability, poor quality of life and global societal burden. In this subgroup analysis from the CONQUER study, ...

    Authors: Rose Okonkwo, Antje Tockhorn-Heidenreich, Chad Stroud, Marie-Ange Paget, Manjit S. Matharu and Cristina Tassorelli
    Citation: The Journal of Headache and Pain 2021 22:113
  38. Trigeminal Neuralgia (TN) is a chronic neurological disease that is strongly associated with neurovascular compression (NVC) of the trigeminal nerve near its root entry zone. The trigeminal nerve at the site o...

    Authors: Judy Alper, Alan C. Seifert, Gaurav Verma, Kuang-Han Huang, Yael Jacob, Ameen Al Qadi, John W. Rutland, Sheetal Patel, Joshua Bederson, Raj K. Shrivastava, Bradley N. Delman and Priti Balchandani
    Citation: The Journal of Headache and Pain 2021 22:112
  39. Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of migraine. In the approval studies, severely affected pa...

    Authors: Armin Scheffler, Hannah Schenk, Sebastian Wurthmann, Michael Nsaka, Christoph Kleinschnitz, Martin Glas and Dagny Holle
    Citation: The Journal of Headache and Pain 2021 22:111
  40. These subgroup analyses of a Phase 3, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of erenumab 70 mg in Japanese migraine patients with/without prior preventive treatmen...

    Authors: Koichi Hirata, Fumihiko Sakai, Takao Takeshima, Noboru Imai, Yasuhiko Matsumori, Ryuji Yoshida, Yotaro Numachi, Cheng Peng, Daniel D. Mikol and Sunfa Cheng
    Citation: The Journal of Headache and Pain 2021 22:110
  41. Headache is a frequent symptom following COVID-19 immunization with a typical onset within days post-vaccination. Cases of cerebral venous thrombosis (CVT) have been reported in adenovirus vector-based COVID-1...

    Authors: David García-Azorín, Thien Phu Do, Andreas R. Gantenbein, Jakob Møller Hansen, Marcio Nattan P. Souza, Mark Obermann, Heiko Pohl, Christoph J. Schankin, Henrik Winther Schytz, Alexandra Sinclair, Guus G. Schoonman and Espen Saxhaug Kristoffersen
    Citation: The Journal of Headache and Pain 2021 22:108
  42. Medication-overuse headache (MOH) is a relatively frequently occurring secondary headache caused by overuse of analgesics and/or acute migraine medications. It is believed that MOH is associated with dependenc...

    Authors: Wei Dai, Enchao Qiu, Yun Chen, Xinbo Xing, Wei Xi, Meichen Zhang, Ke Li, Lixia Tian, Zhao Dong and Shengyuan Yu
    Citation: The Journal of Headache and Pain 2021 22:107
  43. Migraine is a primary headache disorder characterized by recurrent attacks that may have a significant impact on patients’ daily life. Treatment options must often be re-evaluated in light of efficacy, tolerab...

    Authors: M. Koch, Z. Katsarava, C. Baufeld, K. Schuh, A. Gendolla, A. Straube, W. von Pannwitz, W. E. Hofmann and S. Ortler
    Citation: The Journal of Headache and Pain 2021 22:106
  44. Calcitonin gene-related peptide (CGRP) is released from activated meningeal afferent fibres in the cranial dura mater, which likely accompanies severe headache attacks. Increased CGRP levels have been observed...

    Authors: Miriam Risch, Birgit Vogler, Mária Dux and Karl Messlinger
    Citation: The Journal of Headache and Pain 2021 22:105
  45. Neurovascular contact (NVC) is the main cause of primary trigeminal neuralgia (PTN); however, cases of PTN without NVC are still observed. In this study, the Meckel cave (MC) morphology in PTN were analyzed by...

    Authors: Jinzhi Lin, Yong Zhang, Wuming Li, Jianhao Yan and Yiquan Ke
    Citation: The Journal of Headache and Pain 2021 22:104
  46. While pain freedom at 2 h is a key primary outcome for current trials for acute treatment of migraine, the relationship between the degree of head pain and other efficacy measures at 2 h has rarely been explor...

    Authors: Richard B. Lipton, Simin K. Baygani, Stewart J. Tepper, John H. Krege, Raghavendra Vasudeva, Eric M. Pearlman, Paula M. Hauck and Li Shen Loo
    Citation: The Journal of Headache and Pain 2021 22:101